Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
XRP Price Maintains Golden Cross at $3 as Rabby Wallet Integration Nullifies CPI Fears

XRP Price Maintains Golden Cross at $3 as Rabby Wallet Integration Nullifies CPI Fears

CoinspeakerCoinspeaker2025/09/13 16:00
By:By Ibrahim Ajibade Editor Kirsten Thijssen

Ripple (XRP) price consolidates above $3 despite a considerable decline in trading volumes over the weekend. Can bullish expectations on Rabby Wallet integration of XRPL EVM contracts nullify US inflation jitters?

Key Notes

  • XRP price held above $3 on Sept 14 despite a 31,85% trading volume decline to $4,5 billion.
  • Rabby Wallet confirmed XRPL EVM smart contract integration, boosting developer interest and supporting XRP’s resilience at key support.
  • Technical indicators show a golden cross formation, with bullish targets near $3,20 at the $2,94 invalidation level remains intact.

Ripple (XRP) price consolidated above the $3 support on Sunday, Sept 14, keeping intraday losses contained below 3% as broader crypto trading volumes cooled. Market activity slumped after hotter-than-expected US CPI inflation figures tamed hawkish bets on US Federal Reserve rates, ahead of the critical Federal Open Market Committee (FOMC) meeting scheduled for Sept 18.

XRP Price Maintains Golden Cross at $3 as Rabby Wallet Integration Nullifies CPI Fears image 0

Ripple (XRP) Price Action, Sept 14, 2025 | Source: CoinMarketCap

At press time, XRP changed hands near $3.04, dipping 2% on the day. However, spot trading volumes plunged deeper, at 31.85% to hit $4.5 billion, according to CoinMarketCap . Still, the intraday charts showed a mild rebound from the $3 support, around the US noon session.

Rabby Wallet has integrated XRPL EVM chain. @Peersyst pic.twitter.com/gbCGvLupkd

— Rabby Wallet (@Rabby_io) September 13, 2025

A key development strengthening XRP’s resilience over the weekend came late Saturday when Rabby Wallet announced the integration of XRPL’s EVM chain. The wallet, widely used across Ethereum and Solana DeFi communities, confirmed Ripple’s XRPL support in partnership with Peersyst. This marks a new layer of interoperability for Ripple’s blockchain, allowing Ethereum-based smart contracts to run on XRPL.

The expectation of new use cases and increased developer interest from the Rabby wallet integration may have provided a timely counterweight to the CPI tailwinds , keeping XRP price consolidating above $3 at press time.

XRP Price Forecast: Will the Golden Cross Extend Rebound Toward $3.20?

Technical indicators highlight why XRP continues to defend the $3 threshold. On the daily chart, the Super SMA lines (5, 8, and 13-day averages) have completed a bullish alignment, known as a golden cross, with the faster averages crossing above the slower ones. This crossover suggests building momentum in the short term.

XRP’s Bull Bear Power (BBP 13) has also flipped green since Sept 7 and is rising steadily into mid-September. That shift indicates that buyers regained short-term market dominance after closing August on the back foot.

XRP Price Maintains Golden Cross at $3 as Rabby Wallet Integration Nullifies CPI Fears image 1

Ripple (XRP) Price Forecast | Source: TradingView

Without a significant boost in XRP trading volume, current rebound attempts could face stiff resistance around $3.20, where last week’s four-day rally peaked on Saturday.

Conversely, failure to hold the $3.00 level would invalidate the bullish narrative, exposing XRP price to a retest of $2.94, the 13-day SMA support.

For now, holding above $3 with a short-term golden cross support intact strengthens expectations of further upside, provided trading volumes stabilize heading into the Fed rate week.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs